Idiosyncratic liver failure probably associated with atomoxetine: A case report

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 3, 2011, Pages 295-297

  Erdogan, Ayten ^a   Ozcay, Figen ^b   Piskin, Ethem ^a   Karaman, Mehmet Goksin ^c   Bilezikci, Banu ^b   Calik, Mustafa ^d   Tekin, Ishak ^a   Haberal, Mehmet ^b  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c MALTEPE UNIVERSITY   (Turkey)

^d HARRAN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; IMIPRAMINE; METHYLPHENIDATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ABDOMINAL PAIN; ACUTE LIVER FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHILD; DECREASED APPETITE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HEPATIC ENCEPHALOPATHY; HUMAN; LETTER; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TRANSPLANTATION; MALE; PLASMAPHERESIS; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER TRANSPLANTATION; MALE; PROPYLAMINES; SEVERITY OF ILLNESS INDEX;

EID: 79958853124     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2010.0101     Document Type: Letter

References (12)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
2. Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, Regev A, Wernicke JF:Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 31:345-354, 2008. (Pubitemid 351441582)
3. Caballero J, Nahata MC: Atomoxetine hydrochloride for the treatment of attention deficit/hyperactivity disorder. Clin Ther 25:3065-3083, 2003. (Pubitemid 38096145)
4. Cope-Yokoyama S, Finegold MJ, Sturniolo GC, Kim K, Mescoli C, Rugge M, Medici V: Wilson disease: Histopathological correlations with treatment on follow-up liver biopsies. World J Gastroenterol 16:1487-1494, 2010.
5. Hussaini SH, Farrington EA: Idiosyncratic drug-induced liver injury: An overview. Expert Opin Drug Saf 6:673-684, 2007.
6. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH Jr., Fontana RJ, Lee WM, Schilsky ML: Pediatric and Adult Acute Liver Failure Study Groups. Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests. Hepatology 48:1167-1174, 2008.
7. Lewis JH: Drug-induced liver disease. Med Clin North Am 84:1275-1311, 2000.
8. Lim JR, Faught PR, Chalasani NP, Molleston JP: Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 148:831-834, 2006. (Pubitemid 43870084)
9. Pliszka S: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894-921, 2007.
10. Russmann S, Jetter A, Kullak-Ublick GA: Pharmacogenetics of druginduced liver injury. Hepatology 52:748-761, 2010.
11. Stojanovski SD, Casavant MJ, Mousa HM, Baker P, Nahata MC: Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila) 45:51-55, 2007.
12. Visser SN, Lesesne CA, Perou R: National estimates and factors associated with medication treatment for childhood attention-deficit/ hyperactivity disorder. Pediatrics 119 Suppl 1:99-106, 2007.